Spyre Therapeutics, Inc.: Form 10-Q for the period ended Mar 31, 2025
Filed with the SEC on May 8, 2025 and accepted by EDGAR at May 8, 2025, 20:01 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Operating income | 3 months2025-01-01 to 2025-03-31 | −$53.6m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2025-01-01 to 2025-03-31 | −$15.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2025-01-01 to 2025-03-31 | −$44.8m | us-gaap:NetIncomeLoss |
| Operating cash flow | 3 months2025-01-01 to 2025-03-31 | −$41.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2025-03-31 | $48.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-03-31 | $569.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2025-03-31 | $569.8m | us-gaap:Assets |
| Current liabilities | At period end2025-03-31 | $70.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-03-31 | $87.2m | us-gaap:Liabilities |
| Shareholders' equity | At period end2025-03-31 | $482.6m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001636282-25-000049. Last ingested by Listed: Oct 24, 2026, 15:14 ET. Listed shows no prices and gives no investment advice.